PORT WASHINGTON, N.Y. – May 28, 2015 – Pall Corporation (NYSE:PLL), a global leader in filtration, separation and purification, will showcase its Cadence™ Inline Concentrator (ILC) at ACHEMA 2015 in Frankfurt, Germany. Designed to simplify downstream processing, the Cadence Inline Concentrator was recently named Best in Show during the inaugural awards at INTERPHEX 2015 this April. It was selected as the winner for its unique ability to achieve continuous concentration of biomolecules in a single-pass mode, eliminating the recirculation loop traditionally associated with tangential flow filtration. Users report improved product recovery with optimized downstream processing (DSP) steps, reduced buffer usage, and lowered resin costs.
The Cadence ILC’s proprietary flow path comes with a pre-assembled module that does not require a holder, greatly reducing footprint, as well as work and hold-up volumes. The single pass-through design allows for continuous concentration with less protein shear.
“We were thrilled to have the Cadence Inline Concentrator selected as “Best in Show” by industry experts at INTERPHEX,” said Michael Egholm, President of Biopharmaceuticals at Pall Life Sciences. “This is a product that delivers results, and is unlike others on the market. Customers have recorded up to a 31% decrease in cost of goods sold, and up to 66% capital investment savings with the Cadence ILC. Wins like this keep our team focused on innovating solutions to continuously improve bioprocessing, and enable our customers to improve global health.”
The Cadence Inline Concentrator can be coupled with other DSP steps, including pre- and post-chromatography steps, continuous processing or in-line volume reduction, with typical applications including monoclonal antibodies, antibody fragments, recombinant proteins and other biological end products.
See the Cadence Inline Concentrator module, and speak with Pall experts at ACHEMA 2015 booths C74 and F1 at Frankfurt am Main June 15-19. Learn more about Pall at ACHEMA here: http://www.pall.com/main/biopharmaceuticals/event-details.page?id=20140528092832
To learn more about the Cadence Inline Concentrator any time of year, please visit: www.pall.com/cadenceinline
About Pall Corporation
Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Follow us on Twitter @PallCorporation or visit www.pall.com.

Marketing Contact
Erin C. Bush
Senior Manager, Product Marketing
Pall Life Sciences
Telephone: +1 516.801.9637
Email: Erin_Bush@pall.com
Public Relations
Beth Willers, Account Director
Impress Labs
Telephone: +1 415.846.9891
Email: beth@impresslabs.com

More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
April 2020
Pall joins a consortium led by Oxford University in fast-tracking clinical trials for a COVID-19 vaccine beginning April 2020.